Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03126565 · ClinicalTrials.gov registry record · NA
Evaluation of the Philips Lifeline CareSage Risk Assessment System
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 370
- Enrollment target
NCT03126565: Completed NA study, sponsored by Massachusetts General Hospital.
NCT03126565 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 370 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03126565, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 370 participants
- Enrollment target
Study Summary
This study is being done to evaluate the impact of a system called CareSage. The CareSage system is a technology that uses clinical data to monitor, identify and target care to patients at risk of being transported to the hospital. The investigators want to see whether the CareSage system is effective in helping to identify hospital admissions which can be prevented.
Primary Outcome
To assess the impact of the CareSage risk assessment platform and tailored PHH intervention on the 90- and 180- day ED visits.
Interventions
- OTHER Lifeline CareSage Flagging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2017-05-19 |
| Est. Completion | 2019-11-30 |
| Phase | NA |
What the finished NCT03126565 record still lists
NCT03126565 is an interventional study that assigns participants to a tested intervention. The registered 370 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which Lifeline CareSage Flagging is the first listed.
NCT03126565 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03126565 about?
NCT03126565 is a clinical study titled "Evaluation of the Philips Lifeline CareSage Risk Assessment System". This study is being done to evaluate the impact of a system called CareSage. The CareSage system is a technology that uses clinical data to monitor, identify and target care to patients at risk of being transported to the hospital. The investigators want to see whether the CareSage system is effecti...
What is the current status of trial NCT03126565?
This trial is currently completed. It is a NA study. The enrollment target is 370 participants. The study started on 2017-05-19. Estimated completion is 2019-11-30.
What interventions are being tested in trial NCT03126565?
The interventions under investigation include: Lifeline CareSage Flagging (OTHER).
Who is sponsoring clinical trial NCT03126565?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03126565's enrollment target sits among peer trials
370 281st of 2000 higher than 1,720 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- NCT04284436 · 370 participants · NA
Study in Parkinson Disease of Exercise
- NCT05026749 · 370 participants · Phase 3
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
- NCT05125016 · 370 participants · Phase 1
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI